Short answer
Xeris Biopharma Holdings, Inc. (XERS) filed an 8-K current report with the SEC on November 5, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item EX-99.1 (Exhibit EX-99.1). Q3 and nine-month 2026 operating results and business highlights announced for periods ended September 30, 2026.
Xeris Biopharma Holdings, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- Q3 and nine-month 2026 operating results and business highlights announced for periods ended September 30, 2026
- Investor-relevant financial details and management commentary contained in Exhibit 99.1 press release
Item EX-99.1 · Exhibit EX-99.1
- Q3 revenue $107.2M, up 44% YoY, led by Recorlev revenue $71.5M, up 93%
- Gross margin reached 88% versus 85%, while adjusted EBITDA increased to $30.8M from $17.4M
- Full-year 2026 revenue guidance raised to $395M-$405M, signaling stronger near-term commercial momentum
- 2030 revenue outlook raised above $1B from approximately $750M, primarily reflecting faster Recorlev expansion
- 2028 convertible notes fully retired, eliminating approximately $34M debt and $3M annual interest expense
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Xeris Biopharma Holdings, Inc. 8-K filings
Get the next XERS 8-K as it lands
Follow XERS for push alerts, or ask the research agent what this filing means.